Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextranomer is a synthetic, cross-linked hydrophilic dextran polymer used primarily as a wound-cleansing agent and a biocompatible bulking agent. When applied topically to exudative wounds, such as venous stasis or decubitus ulcers, it acts via capillary action to absorb exudate, debris, and microorganisms into its bead structure, facilitating natural healing. In its injectable form (often combined with sodium hyaluronate), it serves as a submucosal bulking agent in the anal canal to treat fecal incontinence by improving bowel control. Historically developed by Pharmacia, it is now marketed under various brands including Solesta and Deflux for internal use and Debrisan for topical wound care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextranomer.